Remove 2003 Remove Biosimilars Remove Chemotherapy
article thumbnail

Beating the Big C

Pharmaceutical Technology

” “Between 2003 and 2005 global sales for cancer-treating drugs grew by 40%.” ” Looming biosimilar legislation and the disregard for patents in the developing world is also threatening the intellectual property, and therefore profit margins, of companies looking to develop cancer drugs.

article thumbnail

Marijuana: Top Ten Reasons for Descheduling, Rescheduling or Not

FDA Law Blog: Biosimilars

Not surprisingly, then-presidential candidate Asa Hutchinson, DEA Administrator from 2001 to 2003, did not sign the letter. The earliest tenured is John Bartels, who served as Administrator from 1973 to 1975. Studies have found that marijuana access has public health benefits by reducing the rates of opioid use and opioid deaths.